Literature DB >> 8274189

Natural history of HLA expression during tumour development.

F Garrido1, T Cabrera, A Concha, S Glew, F Ruiz-Cabello, P L Stern.   

Abstract

HLA expression is frequently altered in tumours compared to the tissue from which they originate. Given the central role of MHC products in the restriction of T-cell recognition, regulation of tumour HLA expression might be a strategy for the evasion of immune surveillance by the malignant cells. Federico Garrido, Peter Stern and colleagues present data from a variety of tumour types, suggesting that HLA class I alterations may occur at a particular step between the development of an in situ lesion and an invasive carcinoma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8274189     DOI: 10.1016/0167-5699(93)90264-L

Source DB:  PubMed          Journal:  Immunol Today        ISSN: 0167-5699


  102 in total

1.  Generation of CD8+ T cells specific for transporter associated with antigen processing deficient cells.

Authors:  E Z Wolpert; M Petersson; B J Chambers; J K Sandberg; R Kiessling; H G Ljunggren; K Kärre
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

2.  Gene expression profile analyses of mice livers injured by Leigongteng.

Authors:  Yong Chen; Xiao-Ming Zhang; Feng-Mei Han; Peng Du; Qi-Song Xia
Journal:  World J Gastroenterol       Date:  2007-07-14       Impact factor: 5.742

Review 3.  Multifunctional molecule ERp57: From cancer to neurodegenerative diseases.

Authors:  Aubryanna Hettinghouse; Ronghan Liu; Chuan-Ju Liu
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

4.  Targeting sarcoma tumor-initiating cells through differentiation therapy.

Authors:  Dan Han; Veronica Rodriguez-Bravo; Elizabeth Charytonowicz; Elizabeth Demicco; Josep Domingo-Domenech; Robert G Maki; Carlos Cordon-Cardo
Journal:  Stem Cell Res       Date:  2017-04-13       Impact factor: 2.020

5.  High expression of adhesion molecules/activation markers with little interleukin-2, interferon gamma, and tumor necrosis factor beta gene activation in fresh tumor-infiltrating lymphocytes from lung adenocarcinoma.

Authors:  E Roussel; M C Gingras; E A Grimm; J A Roth
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

6.  Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition?

Authors:  Simone Kayser; Iris Watermann; Christine Rentzsch; Toni Weinschenk; Diethelm Wallwiener; Brigitte Gückel
Journal:  J Cancer Res Clin Oncol       Date:  2003-06-26       Impact factor: 4.553

7.  New cell lines of gastric and pancreatic cancer: distinct morphology, growth characteristics, expression of epithelial and immunoregulatory antigens.

Authors:  M Heike; O Röhrig; H E Gabbert; R Moll; K H Meyer zum Büschenfelde; W G Dippold; A Knuth
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

8.  Immunodominant minor histocompatibility antigens expressed by mouse leukemic cells can serve as effective targets for T cell immunotherapy.

Authors:  S Pion; P Fontaine; C Baron; M Gyger; C Perreault
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

9.  Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21.

Authors:  Isabel Maleno; Carmen Maria Cabrera; Teresa Cabrera; Laura Paco; Miguel Angel López-Nevot; Antonia Collado; Antonio Ferrón; Federico Garrido
Journal:  Immunogenetics       Date:  2004-07-16       Impact factor: 2.846

10.  HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15.

Authors:  María A Garrido; Teresa Rodriguez; Svitlana Zinchenko; Isabel Maleno; Francisco Ruiz-Cabello; Ángel Concha; Nicolás Olea; Federico Garrido; Natalia Aptsiauri
Journal:  Immunogenetics       Date:  2018-08-25       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.